Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis.

Int Arch Allergy Immunol · 2025 · PMC12401527 · PMID 39827864

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Compared with placebo, treatment with abrocitinib 200 mg/day and upadacitinib 30 mg/day showed an increasing trend in TEAEs.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.